Information Provided By:
Fly News Breaks for December 26, 2019
Dec 26, 2019 | 06:43 EDT
The economics in Sarepta Therapeutics' (SRPT) outside the U.S. Roche (RHHBY) partnership look attractive, Citi analyst Joel Beatty tells investors in a research note. The deal gives Sarepta additional non-dilutive cash, developmental cost sharing for its Duchenne muscular dystrophy gene therapy program, and "a level of validation that manufacturing is headed in the right direction," according to Beatty. The analyst keeps a Buy rating on Sarepta shares with a $177 price target.
News For SRPT;RHHBY From the Last 2 Days
Dec 3, 2021 | 10:16 EST
The Food and Drug Administration announced the approval of Rituxan in combination with chemotherapy for pediatric patients with previously untreated, advanced stage, CD20-positive diffuse large B-cell lymphoma, Burkitt lymphoma, Burkitt-like lymphoma or mature B-cell acute leukemia. Reference Link
Dec 3, 2021 | 07:34 EST
Roche and TIB Molbiol, a newly acquired subsidiary within the Roche Diagnostics division, have added three additional Research Use Only, or RUO, test kits for the detection of mutations present in the novel B.1.1.529 Omicron SARS-CoV-2 variant: VirSNip SARS Spike ins214EPE, VirSNiP SARS-CoV-2 Spike S371L S373P, and VirSNip SARS Spike E484A, the company announced. "The COVID-19 pandemic continues to be an evolving and complex situation, and Roche is committed to responding to healthcare's biggest challenges. The teams at TIB Molbiol have worked around the clock since the new variant emerged, and today we are able to offer a test that can specifically identify the novel B.1.1.529 Omicron SARS-CoV-2 variant to help better understand its spread and behaviour. There is still much to learn about Omicron. It's critical to identify Omicron quickly and accurately, which will help inform ongoing research - including the further development of therapeutics and vaccines - and potentially stop or slow down the advance of this new variant," said Thomas Schinecker, CEO Roche Diagnostics.